Veeva Systems (VEEV) Stock Price, News & Analysis

Company Overview

Veeva Systems, Inc. (NYSE:VEEV) is a cloud-computing company focused on delivering software solutions tailored to the life sciences industry. Founded in 2007 by Peter Gassner and a team of industry veterans, Veeva offers a suite of applications designed to streamline clinical, regulatory, quality, and commercial operations for pharmaceutical, biotechnology, and medical device organizations. Its software-as-a-service (SaaS) model enables companies to manage content, data, and business processes in a secure, compliant environment.

The company’s flagship offering, Veeva Vault, provides a cloud-based content management platform that supports a wide range of functions such as clinical trial operations, regulatory submissions, quality management, and safety management. Veeva CRM, another core product, equips commercial teams with customer relationship management tools optimized for healthcare professionals and key accounts. Additional solutions include Veeva Network for master data management, Veeva Nitro for life sciences data analytics, and Veeva OpenData for global healthcare professional and organization reference data.

With headquarters in Pleasanton, California, Veeva has expanded its global footprint through offices in North America, Europe, Asia Pacific, Latin America, and Japan. The company serves thousands of customers ranging from large multinational pharmaceutical firms to emerging biotech companies. Its industry-specific focus allows Veeva to incorporate regulatory guidance and best practices directly into its applications, helping clients accelerate drug development, ensure product quality, and optimize commercial performance on a global scale.

Under the leadership of CEO Peter Gassner and a seasoned executive team, Veeva has maintained a strong commitment to innovation and customer success. The company invests heavily in research and development to extend its platform capabilities, often partnering with life sciences organizations to address emerging challenges such as digital regulatory submissions and real-world evidence generation. Since its initial public offering in 2013, Veeva has grown both organically and through strategic acquisitions, reinforcing its position as a leading provider of cloud software for the life sciences sector.

Key Stats

• Today's Range: $270.92 to $280.86
• 50-Day Range: $232.96 to $289.99
• 52-Week Range: $177.41 to $291.69
• Volume: 1.66 million shs
• Average Volume: 1.17 million shs
• Market Capitalization: $45.07 billion
• P/E Ratio: 58.44
• Dividend Yield: N/A
• Price Target: $271.04
• Consensus Rating: Moderate Buy

Veeva Systems Stock Analysis - MarketRank™

Veeva Systems scored higher than 82% of companies evaluated by MarketBeat, and ranked 196th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Veeva Systems has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 14 buy ratings, 8 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Veeva Systems has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 6.67%

Earnings Growth

Earnings for Veeva Systems are expected to grow by 6.67% in the coming year, from $4.35 to $4.64 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Veeva Systems is 58.44, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.91.

Price to Earnings Ratio vs. Sector

The P/E ratio of Veeva Systems is 58.44, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.96.

Price to Earnings Growth Ratio

Veeva Systems has a PEG Ratio of 2.23. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Veeva Systems has a P/B Ratio of 7.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.85% of the float of Veeva Systems has been sold short.

Short Interest Ratio / Days to Cover

Veeva Systems has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Veeva Systems has recently decreased by 97.36%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Veeva Systems does not currently pay a dividend.

Dividend Growth

Veeva Systems does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 2.9 / 5
• Environmental Score: -0.79

Percentage of Shares Shorted

6.85% of the float of Veeva Systems has been sold short.

Short Interest Ratio / Days to Cover

Veeva Systems has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Veeva Systems has recently decreased by 97.36%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.16

News Sentiment

Veeva Systems has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 32 news articles for Veeva Systems this week, compared to 20 articles on an average week.

Search Interest

19 people have searched for VEEV on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.

MarketBeat Follows

13 people have added Veeva Systems to their MarketBeat watchlist in the last 30 days. This is an increase of 30% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Veeva Systems insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $659,381.00 in company stock.

Percentage Held by Insiders

10.30% of the stock of Veeva Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.20% of the stock of Veeva Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VEEV Stock Analysis - Frequently Asked Questions

How have VEEV shares performed this year?

Veeva Systems' stock was trading at $210.25 at the beginning of 2025. Since then, VEEV stock has increased by 31.2% and is now trading at $275.8160.

How were Veeva Systems' earnings last quarter?

Veeva Systems Inc. (NYSE:VEEV) announced its earnings results on Wednesday, May, 28th. The technology company reported $1.97 EPS for the quarter, beating analysts' consensus estimates of $1.74 by $0.23. The company's revenue for the quarter was up 16.7% compared to the same quarter last year.
Read the conference call transcript.

Does Veeva Systems have any subsidiaries?

Veeva Systems subsidiaries include Veeva RTSM, Veracity Logic, Learnaboutgmp, Physicians World, Veeva Crossix, Zinc Ahead Ltd, Selligy, and AdvantageMS.

Who are Veeva Systems' major shareholders?

Veeva Systems' top institutional shareholders include Swedbank AB (0.64%), Seilern Investment Management Ltd (0.21%), Zevenbergen Capital Investments LLC (0.13%) and E. Ohman J or Asset Management AB (0.10%). Insiders that own company stock include Matthew J Wallach, Thomas D Schwenger, Alan Mateo, Eleni Nitsa Zuppas, Paul Edward Chamberlain, Paul J Sekhri, Michele O'connor, Jonathan Faddis, Timothy S Cabral, Mary Lynne Hedley, Priscilla Hung and Peter P Gassner.
View institutional ownership trends.

How do I buy shares of Veeva Systems?

Shares of VEEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Veeva Systems own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Veeva Systems investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM).

Company Calendar

• Last Earnings: 5/28/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/27/2025
• Fiscal Year End: 1/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Computer Software
• Current Symbol: NYSE:VEEV
• CIK: 1393052
• Web: www.veeva.com
• Phone: (925) 452-6500
• Fax: 925-452-6504
• Employees: 7,291
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Veeva Systems: $271.04
• High Price Target: $329.00
• Low Price Target: $192.00
• Potential Upside/Downside: -1.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.72
• Trailing P/E Ratio: 58.44
• Forward P/E Ratio: 63.41
• P/E Growth: 2.23
• Net Income: $714.14 million
• Net Margins: 27.34%
• Pretax Margin: 35.42%
• Return on Equity: 13.96%
• Return on Assets: 11.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.60
• Quick Ratio: 4.60

Sales & Book Value

• Annual Sales: $2.75 billion
• Price / Sales: 16.41
• Cash Flow: $4.67 per share
• Price / Cash Flow: 59.05
• Book Value: $35.87 per share
• Price / Book: 7.69

Miscellaneous

• Outstanding Shares: 163,410,000
• Free Float: 146,581,000
• Market Cap: $45.07 billion
• Optionable: Optionable
• Beta: 0.98